Forza Wealth Management LLC Sells 200 Shares of Zoetis Inc. $ZTS

Forza Wealth Management LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,034 shares of the company’s stock after selling 200 shares during the quarter. Forza Wealth Management LLC’s holdings in Zoetis were worth $473,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lindbrook Capital LLC boosted its stake in shares of Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after buying an additional 65 shares during the last quarter. Scott & Selber Inc. grew its holdings in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after purchasing an additional 67 shares during the period. Secure Asset Management LLC grew its holdings in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after purchasing an additional 68 shares during the period. Quotient Wealth Partners LLC lifted its position in shares of Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after acquiring an additional 72 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. lifted its position in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company’s stock valued at $287,000 after acquiring an additional 73 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 2.1%

Zoetis stock opened at $146.12 on Wednesday. The business has a fifty day moving average of $150.16 and a two-hundred day moving average of $155.45. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $64.76 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.30 and a beta of 0.88. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.